PMID- 23451253
OWN - NLM
STAT- MEDLINE
DCOM- 20140121
LR  - 20240318
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 2
DP  - 2013
TI  - The therapeutic role of monocyte chemoattractant protein-1 in a renal tissue 
      engineering strategy for diabetic patients.
PG  - e57635
LID - 10.1371/journal.pone.0057635 [doi]
LID - e57635
AB  - In this study we aim to boost the functional output of the intra-kidney islet 
      transplantation for diabetic patients using a tissue engineered polymeric 
      scaffold. This highly porous electrospun scaffold featured randomly distributed 
      fibers composed of polycaprolactone (PCL) and poliglecaprone (PGC). It 
      successfully sustained murine islets in vitro for up to 4 weeks without detected 
      cytotoxicity. The in vivo study showed that the islet population proliferated by 
      89% within 12 weeks when they were delivered by the scaffold but only 18% if 
      freely injected. Correspondingly, the islet population delivered by the scaffold 
      unleashed a greater capability to produce insulin that in turn further drove down 
      the blood glucose within 12 weeks after the surgery. Islets delivered by the 
      scaffold most effectively prevented diabetic deterioration of kidney as evidenced 
      by the lack of a kidney or glomerular enlargement and physiological levels of 
      creatinine, urea nitrogen and albumin through week 12 after the surgery. Unlike 
      traditional wisdom in diabetic research, the mechanistic study suggested that 
      monocytes chemoattractant protein-1 (MCP-1) was responsible for the improved 
      preservation of renal functions. This study revealed a therapeutic role of MCP-1 
      in rescuing kidneys in diabetic patients, which can be integrated into a tissue 
      engineered scaffold to simultaneously preserved renal functions and islet 
      transplantation efficacy. Also, this study affords a simple yet effective 
      solution to improve the clinical output of islet transplantation.
FAU - Yin, Hao
AU  - Yin H
AD  - Department of Surgery, Shanghai Changzheng Hospital, Shanghai Second Military 
      Medical University, Shanghai, China.
FAU - Gao, Ming
AU  - Gao M
FAU - Leoni, Lara
AU  - Leoni L
FAU - Han, Huifang
AU  - Han H
FAU - Zhang, Xing
AU  - Zhang X
FAU - Fu, Zhiren
AU  - Fu Z
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130225
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Blood Glucose)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Insulin)
SB  - IM
MH  - Animals
MH  - Blood Glucose/metabolism
MH  - Chemokine CCL2/*metabolism/*pharmacology
MH  - Diabetes Mellitus, Experimental/blood/*surgery
MH  - Humans
MH  - Insulin/metabolism
MH  - Islets of Langerhans/metabolism/physiology
MH  - Islets of Langerhans Transplantation/*methods
MH  - Kidney/*surgery
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Tissue Engineering/*methods
PMC - PMC3581514
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2013/03/02 06:00
MHDA- 2014/01/22 06:00
PMCR- 2013/02/25
CRDT- 2013/03/02 06:00
PHST- 2012/08/19 00:00 [received]
PHST- 2013/01/23 00:00 [accepted]
PHST- 2013/03/02 06:00 [entrez]
PHST- 2013/03/02 06:00 [pubmed]
PHST- 2014/01/22 06:00 [medline]
PHST- 2013/02/25 00:00 [pmc-release]
AID - PONE-D-12-26292 [pii]
AID - 10.1371/journal.pone.0057635 [doi]
PST - ppublish
SO  - PLoS One. 2013;8(2):e57635. doi: 10.1371/journal.pone.0057635. Epub 2013 Feb 25.